|Home||» Products||» Pharmaceutical Medicine||» Prograf|
Prograf is the medicine with active ingredient Tacrolimus. Tacrolimus is also manufactured by differ manufacturers and sold in differ countries under the trade names Advagraf, Fujimycin, Prograf, Protopic. All these medicines are original brand name medicines or pharmaceutical analogues.
Inadvertent, unintentional or unsupervised switching of immediate- or prolonged-release formulations of tacrolimus is unsafe. This can lead to graft rejection or increased incidence of side effects, including under- or over-immunosuppression, due to clinically relevant differences in systemic exposure to tacrolimus. Patients should be maintained on a single formulation of tacrolimus with the corresponding daily dosing regimen; alterations in formulation or regimen should only take place under the close supervision of a transplant specialist (see sections 4.4 and 4.8). Following conversion to any alternative formulation, therapeutic drug monitoring must be performed and dose adjustments made to ensure that systemic exposure to tacrolimus is maintained.